| abstract |
The invention refers to novel isoxazole and 4,5-dihydroisoxazole derivatives of formula (I) being suitable for the treatment of especially a pathological alteration of the central nervous system and/or a cardiovascular and/or gastrointestinal disease, furthermore pharmaceutical compositions containing the above derivatives, and a process for the preparation of the novel compounds. Specifically, the invention refers to isoxazole derivatives of formula (I). In formula (I), A and B represent, independently, a hydrogen atom, or A forms, together with B, a valence bond; Z stands for a hydrogen atom, a halo atom, a C1-4 alkyl group, a trifluoromethyl group or one or two C1-4 alkoxy group(s); R?1 and R2¿ mean, independently, a C¿1-6? alkyl group or a C3-7 cycloalkyl group; or R?1 and R2¿ form, together with the nitrogen atom they are attached to and optionally with one or more further nitrogen and/or oxygen atom(s), a 5 to 8-membered heterocyclic ring that can be substituted by a C¿1-4? alkyl group, a (C1-4 alkyl) phenyl group, a (C1-4 alkoxy) phenyl group, a di(C1-4 alkoxy) phenyl group, a halophenyl group, a trifluoromethylphenyl group or a furoyl group; m has a value of 0 or 1; n has a value of 0 or 1. |